


LISBON - Oxford Drug Design, a promising startup in the field of pharmaceuticals and biomedicine, features knowledgeable experts and tech that makes searching for a cure for any disease more affordable, time-effective, and accurate than previously possible. A process that once would have taken decades might now be just a few years away. Alan Roth, chief executive at Oxford Drug Design in the United Kingdom, recently sat down with The Yuan journalist and artificial intelligence (AI) expert Oladimeji Ewumi to discuss how his company is pioneering a new era of therapeutics and AI that will potentially transform how the world approaches drug design.
Alan, can you share the inspiration behind founding Oxford Drug Design and how AI plays such a pivotal role in your approach to drug discovery?
Oxford Drug Design was originally spun out from the chemistry laboratory of Prof Graham Richards at Oxford
The content herein is subject to copyright by The Yuan. All rights reserved. The content of the services is owned or licensed to The Yuan. Such content from The Yuan may be shared and reprinted but must clearly identify The Yuan as its original source. Content from a third-party copyright holder identified in the copyright notice contained in such third party’s content appearing in The Yuan must likewise be clearly labeled as such.



